MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.90
+0.12
+2.08%
Opening 14:47 05/14 EDT
OPEN
5.86
PREV CLOSE
5.78
HIGH
5.95
LOW
5.79
VOLUME
249.74K
TURNOVER
--
52 WEEK HIGH
30.10
52 WEEK LOW
3.922
MARKET CAP
148.99M
P/E (TTM)
-4.2670
1D
5D
1M
3M
1Y
5Y
Heat Biologics names Anthony Manning as chief scientific advisor
Heat Biologics ([[HTBX]] -1.8%) announces the appointment of Anthony Manning as the company's chief scientific advisor.Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics’ product portfolio.He brings over
Seekingalpha · 4d ago
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
GlobeNewswire · 4d ago
Heat Biologics EPS misses by $0.01, misses on revenue
Heat Biologics (HTBX): Q1 GAAP EPS of -$0.31 misses by $0.01.Revenue of $0.54M (-40.0% Y/Y) misses by $0.08M.As of March 31, 2021, the Company had approximately $132 million in cash,
Seekingalpha · 05/05 11:58
Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs
Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today provid...
GlobeNewswire · 05/05 11:46
10-Q: HEAT BIOLOGICS, INC.
(EDGAR Online via COMTEX) -- ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 05/05 11:44
BRIEF-Heat Biologics Reports Q1 Loss Per Share Of $0.31
reuters.com · 05/05 11:43
Heat Biologics Q1 EPS $(0.31) Up From $(0.77) YoY
Heat Biologics (NASDAQ:HTBX) reported quarterly losses of $(0.31) per share. This is a 59.74 percent increase over losses of $(0.77) per share from the same period last year.
Benzinga · 05/05 11:32
Heat Biologics Stock Appears To Be Significantly Overvalued
GuruFocus News · 04/27 15:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HTBX. Analyze the recent business situations of Heat Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HTBX stock price target is 26.00 with a high estimate of 40.00 and a low estimate of 19.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 2.33M
% Owned: 9.21%
Shares Outstanding: 25.25M
TypeInstitutionsShares
Increased
10
273.01K
New
9
488.55K
Decreased
10
12.91K
Sold Out
16
46.24K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.58%
Pharmaceuticals & Medical Research
+1.14%
Key Executives
Chairman/President/Chief Executive Officer/Director
Jeffrey Wolf
Chief Financial Officer
William Ostrander
Lead Director/Independent Director
John Prendergast
Independent Director
John Monahan
Independent Director
Edward Smith
No Data
About HTBX
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HTBX stock methods without spending real money on the virtual paper trading platform.